MARKET

RANI

RANI

Rani Therapeutics Holdings, Inc.
NASDAQ
0.7649
-0.0457
-5.64%
Opening 13:13 03/30 EDT
OPEN
0.8301
PREV CLOSE
0.8106
HIGH
0.8416
LOW
0.7031
VOLUME
2.20M
TURNOVER
--
52 WEEK HIGH
3.870
52 WEEK LOW
0.3870
MARKET CAP
94.61M
P/E (TTM)
-1.7047
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RANI last week (0323-0327)?
Weekly Report · 11h ago
Rani Therapeutics files initial beneficial ownership statement; Chief Technical Officer Alireza Javadi reports 10,075 Class A shares
Reuters · 2d ago
Rani Therapeutics Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Mirum Pharmaceuticals (MIRM) and NovoCure (NVCR)
TipRanks · 3d ago
Rani Therapeutics' net loss narrows in Q4 as costs fall
Reuters · 4d ago
Rani Therapeutics GAAP EPS of -$0.07 in-line, revenue of $1.46M misses by $3.54M
Seeking Alpha · 4d ago
Rani Therapeutics FY2025 net loss narrows 27.6% to $41 million; revenue rises 58.9% to $1.6 million
Reuters · 4d ago
More
About RANI
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).

Webull offers Rani Therapeutics Holdings Inc stock information, including NASDAQ: RANI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RANI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RANI stock methods without spending real money on the virtual paper trading platform.